First-in-Human Dose Study of the Novel Transforming Growth Factor-β Receptor I Kinase Inhibitor LY2157299 Monohydrate in Patients with Advanced Cancer and Glioma

PURPOSE: TGFβ signaling plays a key role in tumor progression, including malignant glioma. Small-molecule inhibitors such as LY2157299 monohydrate (LY2157299) block TGFβ signaling and reduce tumor progression in preclinical models. To use LY2157299 in the treatment of malignancies, we investigated i...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Clin Cancer Res
Autori principali: Rodon, Jordi, Carducci, Michael A., Sepulveda-Sánchez, Juan M, Azaro, Analia, Calvo, Emiliano, Seoane, Joan, Braña, Irene, Sicart, Elisabet, Gueorguieva, Ivelina, Cleverly, Ann L., Pillay, N. Sokalingum, Desaiah, Durisala, Estrem, Shawn T., Paz-Ares, Luis, Holdhoff, Matthias, Blakeley, Jaishri, Lahn, Michael M., Baselga, Jose
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2014
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4337847/
https://ncbi.nlm.nih.gov/pubmed/25424852
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-14-1380
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi